Epitopes for Protective Immunity Targeting Antigens of Pathogen and/or Host (EPITAPH): Towards Novel Vaccines Against HIV and Other Medically Challenging Infections by Salvador Eugenio C. Caoili
OPINION ARTICLE
published: 10 June 2014
doi: 10.3389/fimmu.2014.00270
Epitopes for Protective Immunity Targeting Antigens of
Pathogen and/or Host (EPITAPH): towards novel vaccines
against HIV and other medically challenging infections
Salvador Eugenio C. Caoili*
Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila, Philippines
*Correspondence: badong@post.upm.edu.ph
Edited by:
Marc H. V. Van Regenmortel, University of Strasbourg, France
Reviewed by:
Britta E. Wahren, Karolinska Institutet, Sweden
Dimiter S. Dimitrov, National Institutes of Health, USA
Lucia Lopalco, San Raffaele Scientific Institute, Italy
Keywords: epitopes, immunity, antibodies, pathogens, hosts, vaccines, HIV, AIDS
Antiretroviral therapy (ART) currently
enables long-term survival of persons liv-
ing with HIV (PLWH), but the respite
from escalating pandemic AIDS-related
deaths is undermined by both emer-
gence of drug-resistant HIV and failure to
develop HIV vaccines (1). Such reliance
on drugs instead of vaccines is arguably
a defeatist strategy against infectious dis-
eases in the face of inevitable pathogen
drug resistance. Still, the development of
anti-infective vaccines is presently con-
strained by the exclusion of host self epi-
topes from candidate vaccine components.
This aims to avoid inducing autoreactive
host immune responses, some of which
might yet be exploited to prevent or control
infection by disrupting key host–pathogen
interactions, notably using antibodies that
bind critical epitopes and thereby steri-
cally hinder molecular recognition (e.g.,
between virus and host cell). Classic
vaccine-induced antibody responses are
intended to target only pathogen-derived
antigens or analogs thereof (e.g., recom-
binant or synthetic fragments); however,
pathogen immune evasion may occur
especially where epitope variability gen-
erates immunodominant decoy epitopes
that elicit non-protective and possibly even
harmful (e.g., infection-enhancing) anti-
body responses. Although vaccine design
might be attempted to elicit protective
antibody responses only against carefully
selected pathogen epitopes, this is bio-
logically unrealistic if based on a reduc-
tionist approach whereby individual epi-
topes are evaluated in isolation from
one another, neglecting their functional
interdependence in the context of host
infection and immunity (2). Extending the
notion of synergistic simultaneous target-
ing of structurally distinct epitopes, both
pathogen-derived and host self epitopes
are plausible targets of antibody-mediated
protective immunity. As both pathogen
and host contribute to pathogenesis of
infectious disease (3), vaccination poten-
tially can limit overall host damage due to
both pathogen-associated (i.e., virulence)
and host-associated (i.e., immune) factors,
with some degree of host-induced dam-
age being acceptable in place of more
extensive pathogen-induced damage. An
HIV vaccine thus might elicit antibodies
that bind the gp120 receptor (CD4) or
co-receptors (CCR4 and CCR5) to inter-
rupt the viral replication cycle. This would
be self-defeating if it resulted in excessive
harm due to autoimmune host damage
(e.g., manifest as quantitative or qualitative
deficits of CD4+ cells, resulting in severe
immunodeficiency), but tantalizing alter-
native scenarios are suggested by cases of
natural resistance to HIV-1 infection that
feature anti-CD4 autoantibodies (4).
Although binding of host self anti-
gens by antibodies risks host damage,
such binding may occur without result-
ing in appreciable harm. In support of
this view, an apparent lack of pathologi-
cal manifestations has been noted among
healthy individuals who developed cir-
culating antiplatelet autoantibodies (e.g.,
binding the platelet glycoprotein complex
gpIb-IX) subsequent to immunization
with recombinant HIV gp160 (5); and
certain rare broadly neutralizing HIV-1
antibodies (e.g., to the 2F5 and 4E10 epi-
topes of HIV gp41) have been shown
to exhibit polyspecific autoreactivity [e.g.,
such that the 2F5 and 4E10 antibodies
bind the host phospholipid cardiolipin (6)
yet also bind other human autoantigens
including kynureninase and splicing factor
3b subunit 3, respectively (7)]. Such bind-
ing of host self antigens by autoantibodies
entails broken self tolerance, which is typ-
ically difficult to induce (consistent with
the rarity of 2F5- and 4E10-like antibod-
ies, presumably reflecting an evolutionary
adaptation that avoids autoimmune host
damage); but in spite of this, immunization
with recombinant constructs comprising
CCR5-derived sequences recently has been
shown (using murine and simian models)
to elicit apparently non-deleterious anti-
CCR5 antibody responses that block HIV
(8) or SIV (9) infectivity, which points to
the prospect of developing safe and effi-
cacious HIV vaccines that induce protec-
tive immunity based on antibody targeting
of judiciously selected host self epitopes
(rather than whole autoantigens).
Hence, functional epitope mapping
conceivably could delineate host self epi-
topes as targets for antibody binding
in vivo, to block infection without pro-
ducing excessive damage. Such targeting
of host self epitopes might be suffi-
cient to block infection (e.g., if binding
of the epitopes by antibodies in itself
imposed steric hindrance that directly pre-
cluded crucial biomolecular interactions);
otherwise, infection still might be blocked
by simultaneous binding of both host
self- and pathogen-associated epitopes by
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synergistically acting antibodies (e.g., with
sufficient steric hindrance realized only
between host- and pathogen-bound anti-
bodies). Furthermore, host self epitopes
tend to be highly conserved, which could
facilitate vaccine design for entire host
populations. The risk–benefit trade-off
posed by host-reactive antibody-mediated
immunity could be explored initially
through passive immunization with mon-
oclonal antibodies (mAbs), before com-
mitting to active-immunization strategies
(e.g., that employ prophylactic or thera-
peutic vaccines). The mAbs could be devel-
oped in tandem with specific antidotes
(e.g., anti-idiotypic constructs that pre-
vent antibody binding of host self epi-
topes) for treating any adverse reactions
that might occur, for instance, due to
effector mechanisms such as complement
activation and antibody-dependent cell-
mediated cytotoxicity (ADCC). Antibody-
mediated complement activation might be
minimized by avoiding the juxtaposition
of target epitopes (e.g., by targeting only
one epitope per antigen), whereas dam-
age due to any activated complement could
be mitigated by complement-inactivating
agents (e.g., eculizumab); and damage due
to ADCC might be addressed by sup-
pression of natural killer (NK) cell activ-
ity. Such complications could pose barri-
ers to regulatory approval, albeit perhaps
less so for therapeutic versus prophylac-
tic vaccines particularly where net benefit
(e.g., gained by obviating ART for PLWH)
would be strongly compelling. Neverthe-
less, either or both complement activation
and ADCC still might contribute to net
benefit if they actually decreased pathogen
replication [e.g., possibly with antibod-
ies to the scavenger receptor CD36, which
have been shown to inhibit HIV-1 release
from infected macrophages by clustering
newly formed virions at their site of bud-
ding (10)].
Beyond HIV, other medically challeng-
ing infections likewise might be con-
trolled through antibody targeting of host
self epitopes. In a manner analogous to
the blocking of HIV infection by anti-
bodies that bind CD4, CCR4, or CCR5,
infection due to other pathogens can be
blocked by antibodies and antibody-like
constructs that bind appropriate target epi-
topes on host cells; this is exemplified by
the anti-infective activity of multivalent
recombinant antibody fusion proteins that
bind intercellular adhesion molecule 1
(ICAM-1), particularly against human rhi-
novirus (for which ICAM-1 serves as
the major host receptor) (11). Anti-
infective immunity also may be medi-
ated by antibodies that selectively tar-
get modified-self epitopes of infected host
cells, such as band-3 neotopes of para-
sitized erythrocytes in falciparum malaria
(12). Yet another strategy might be the
use of anti-idiotypic antibodies against
infection-enhancing antibodies, which is
potentially applicable where antibody-
dependent enhancement (ADE) of infec-
tion [e.g., with HIV, a wide variety of other
viruses and even cellular pathogens includ-
ing bacteria and protozoa (13)] contributes
to pathogenesis, although caution would
be warranted to avoid adverse iatrogenic
effects (e.g., autoimmune damage medi-
ated by antibodies produced against the
anti-idiotypic antibodies, resulting from
molecular mimicry of host self epitopes by
the anti-idiotypic antibodies).
The scheme described herein thus
shifts the focus of immunity-oriented
approaches in health care, from immune
destruction of specific targets back to the
original object of vaccination, namely host
protection against disease. This widens the
scope of vaccines and immunotherapeu-
tics, by placing due emphasis on immune
targeting of host self epitopes as a poten-
tial means for host protection associated
with negligible or justifiably limited host
damage. More generally, immune target-
ing of epitopes may be broadly concep-
tualized in terms of high-level functional
outcomes including both familiar con-
sequences of conventional immunization
regimens (e.g., for prophylaxis or ther-
apy primarily based on targeted immune
destruction of microbial pathogens and
host-derived malignant cells) as well as
less obvious and possibly even counter-
intuitive but nonetheless beneficial results
(e.g., host resistance to infections that is at
least partly based on non-destructive bind-
ing of antibodies to host self epitopes).
Such a perspective provides the basis for
an expanded paradigm of biomedically
enhanced immune function, the essence of
which is concisely expressed as the idea
of epitopes for protective immunity tar-
geting antigens of pathogen and/or host
(EPITAPH).
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